Team
health

DIC Syndrome Calculator

Disseminated intravascular coagulopathy (DIC) is a life-threatening condition where systemic activation of blood clotting depletes platelets and clotting factors, paradoxically causing both thrombosis and severe bleeding. Clinicians use laboratory parameters—platelet count, fibrin degradation products, prothrombin time, and fibrinogen—to quantify DIC risk in critically ill patients. This calculator integrates these values to stratify risk, supporting clinical decision-making in sepsis, trauma, obstetric emergencies, and malignancy-related coagulopathy.

Last updated:

Creators Łucja Zaborowska, MD, PhD
662 people find this calculator helpful

Understanding DIC: The Coagulation Paradox

Disseminated intravascular coagulopathy represents a haematological crisis in which the coagulation cascade becomes globally activated, consuming platelets and clotting factors at a rate that far exceeds the body's ability to replace them. The result is a dual pathology: widespread microvascular thrombosis starves tissues of oxygen whilst simultaneously uncontrolled consumption of pro-coagulants leaves the patient defenceless against haemorrhage.

DIC is not a primary disease but rather a secondary syndrome arising from a triggering insult. Common precipitants include:

  • Sepsis and severe infection – the most frequent cause, often gram-negative organisms releasing endotoxin
  • Massive trauma – particularly crush injuries and polytrauma with tissue release
  • Obstetric complications – placental abruption, amniotic fluid embolism, and retained dead fetus
  • Acute haematologic malignancy – especially acute promyelocytic leukaemia
  • Organ injury and failure – liver cirrhosis, acute pancreatitis
  • Transfusion reactions – incompatible blood products triggering complement activation

Clinical Presentation and Laboratory Markers

Acute DIC manifests as a medical emergency with overlapping ischaemic and haemorrhagic features. Patients may present with uncontrolled bleeding from venepuncture sites, mucous membranes, or surgical wounds alongside signs of organ hypoperfusion—acute kidney injury, altered mental status, or shock.

Laboratory findings are characteristic and form the basis of this calculator:

  • Thrombocytopenia (platelet count <100 × 10⁹/L) due to consumption
  • Elevated fibrin degradation products and D-dimer reflecting ongoing fibrinolysis
  • Prolonged prothrombin time (PT) and elevated INR from depletion of factors II, V, VII, X
  • Low fibrinogen (<100 mg/dL in severe cases) after rapid consumption

Serial monitoring of these parameters tracks disease progression and treatment response better than single measurements.

DIC Risk Scoring

The DIC calculator combines four laboratory parameters into a composite scoring system. Each variable reflects a different aspect of the coagulation derangement: platelet consumption, fibrin generation, hepatic synthetic function, and clotting factor depletion.

DIC Score = Platelet Count + Fibrin Markers + Prothrombin Time + Fibrinogen

  • Platelet Count — Absolute number of platelets (× 10⁹/L). Values <100 contribute higher risk points.
  • Fibrin Markers — Elevation of fibrin degradation products or D-dimer above normal range. Marked elevation indicates active coagulation consumption.
  • Prothrombin Time — Normalised ratio (INR) or prolongation in seconds. Reflects depletion of vitamin K-dependent factors (II, VII, IX, X).
  • Fibrinogen Level — Plasma fibrinogen concentration (mg/dL). Progressive decline below 100 mg/dL signals severe consumption.

Critical Considerations in DIC Assessment

Laboratory values must be interpreted alongside clinical context; no single test defines DIC.

  1. Acute versus chronic DIC — Acute DIC develops over hours to days with fulminant bleeding and organ failure, whilst chronic DIC (seen in some malignancies) may show laboratory derangements with fewer symptoms. Treatment strategies differ markedly.
  2. HELLP syndrome overlap — Severe preeclampsia with haemolysis, elevated liver enzymes, and low platelets (HELLP) can mimic DIC. Key distinction: HELLP shows abnormal liver function and bilirubin without markedly elevated fibrin degradation products; DIC always shows fibrinolysis.
  3. Serial measurement essential — Single laboratory snapshots may not capture DIC progression. Repeat testing at 6–24 hour intervals better reflects consumption kinetics and informs blood product transfusion decisions.
  4. Transfusion thresholds — Aggressive correction of platelets, fibrinogen, and PT with blood products can paradoxically fuel DIC by providing more substrate for consumption. Balance haemostatic correction against careful fluid management and treatment of underlying cause.

Management and Prognosis

DIC management centres on two pillars: eliminating the triggering condition and supportive haemostatic therapy.

First priority: Aggressively treat infection, control bleeding from obstetric or surgical sources, or manage malignancy. Without addressing the underlying cause, transfusions alone will fail.

Haemostatic support: Replace consumed blood components—fresh frozen plasma provides fibrinogen and clotting factors, platelet concentrates restore thrombocyte mass, and cryoprecipitate provides additional fibrinogen. Heparin is controversial; it may prevent thrombosis in selected cases but increases bleeding risk.

Mortality from acute DIC remains high (30–50%) despite advances, though survival is possible with rapid recognition and intensive supportive care. Survivors may face permanent organ dysfunction—renal failure requiring dialysis, hepatic insufficiency, or tissue loss necessitating amputation. Early transfer to a centre capable of providing extracorporeal support (ECMO) should be considered in refractory cases.

Frequently Asked Questions

What laboratory abnormalities define disseminated intravascular coagulopathy?

DIC is characterised by a constellation of laboratory findings: thrombocytopenia (typically <100 × 10⁹/L), marked elevation of fibrin degradation products and D-dimer reflecting ongoing fibrinolysis, prolonged prothrombin time and activated partial thromboplastin time from factor depletion, and declining fibrinogen (<100 mg/dL in severe disease). No single test diagnoses DIC; rather, the combination of these abnormalities alongside clinical evidence of bleeding or thrombosis establishes the diagnosis.

What are the leading causes of DIC in clinical practice?

Sepsis—particularly from gram-negative organisms—is the most common trigger in hospitalised patients. Severe trauma, obstetric emergencies (placental abruption, amniotic fluid embolism), and acute leukaemia account for the majority of remaining cases. Rarer causes include fulminant hepatic failure, massive transfusion, severe pancreatitis, and incompatible blood transfusion reactions. Identifying and treating the underlying trigger is essential; DIC itself is a consequence, not a primary disease.

Can DIC be prevented in at-risk patients?

Primary prevention of DIC is limited because it arises unpredictably from acute illness. Optimising management of chronic conditions—tight glycaemic control in diabetes, blood pressure management in hypertension, and adherence to antimicrobial prophylaxis—may reduce infection risk. In obstetrics, careful monitoring for abruption and prompt delivery in preeclampsia minimise DIC incidence. Once acute illness develops, rapid diagnosis and treatment of the trigger (sepsis, bleeding source, malignancy) is the most effective preventive strategy.

How does DIC differ from HELLP syndrome in pregnancy?

Both conditions present with thrombocytopenia and can occur in pregnancy, but their origins and laboratory patterns differ. HELLP syndrome (haemolysis, elevated liver enzymes, low platelets) is a manifestation of severe preeclampsia characterised by mechanical haemolysis, hepatic injury with elevated transaminases and bilirubin, and thrombocytopenia—but fibrin degradation products remain normal. DIC, by contrast, shows markedly elevated fibrin split products and D-dimer alongside prolonged PT. HELLP treatment is delivery of the fetus; DIC requires treatment of the underlying cause alongside blood product support.

What is the role of heparin in DIC treatment?

Heparin's use in DIC remains controversial. In cases where thrombosis predominates over bleeding—such as acute promyelocytic leukaemia with microangiopathic haemolytic anaemia—anticoagulation may prevent further microvascular occlusion. However, in haemorrhage-dominant DIC, heparin increases bleeding risk without clear benefit. Low-molecular-weight heparin is preferred over unfractionated heparin if used, and decisions should be individualised with close monitoring of platelet count and fibrinogen trends.

What is the survival rate for patients with acute DIC?

Mortality from acute DIC ranges from 30–50%, depending on the underlying cause, age, and comorbidities. Sepsis-related DIC carries worse prognosis than trauma-related DIC. Survival depends critically on rapid recognition, immediate treatment of the trigger, and aggressive supportive care including vasopressor support and organ-supportive therapies. Survivors often experience permanent sequelae such as chronic renal failure, hepatic dysfunction, or amputation from tissue necrosis. Early referral to intensive care with capability for extracorporeal support substantially improves outcomes.

More health calculators (see all)

Sodium Change in Hypertriglyceridemia Calculator Macro Calculator Ideal Weight Calculator Adjusted Age Calculator South Africa Vaccine Queue Calculator Free Testosterone Calculator Pack Years Calculator Diabetic Ketoacidosis Calculator